Abiomed

ABIOMED (NASDAQ:ABMD) Issues Quarterly Earnings Results - TheOlympiaReport | 2/9/2020

… share for the quarter, topping the Thomson Reuters’ consensus estimate of $1.09 by $0.42, RTT News reports. The firm had revenue of $221.60 million for the quarter, compared to analysts’ expectations of $226.92 million. ABIOMED had a net margin of 29.14% and a return on equity of 19.53%. The company’s quarterly revenue was up 10.5% compared to the same quarter last year. During the same period in the prior year …

Cramer’s lightning round: Abiomed was on ‘fire’ then it ‘collapsed’ | CNBC | 2/8/2020

… had a big pop. It’s a big speculative stock. I’d rather buy Tesla on the way down because they have battery power. They’ve got a good thing going.” VIDEO 4:42 04:42 Cramer’s lightning round: Abiomed was on ‘fire’ then it ‘collapsed’ Mad Money with Jim Cramer Disclosure: Cramer’s charitable trust owns shares of General Electric. Questions for Cramer? Call Cramer: 1-800-743-CNBC Want to take a deep dive into Cramer’s …

Follow Abiomed:    

Abiomed Crushed Its Earnings Estimates, but the Market Wasn’t Impressed | 2/7/2020

… a line of murder mysteries, including Whodidit in the Supreme Court? and Whodidit With a Senator? The majority of what he knows about stocks he learned right here at the Motley Fool. On Thursday, Abiomed ( NASDAQ:ABMD ) announced its results for its third quarter, delivering a major beat on its bottom-line estimates. The market was expecting $1.09 a share in earnings, but got $1.51 a share instead. Profits were …

BDX, GLOP among premarket losers | Seeking Alpha | 2/6/2020

Abiomed (NASDAQ: ABMD ) -8% on Q3 earnings . Peloton Interactive (NASDAQ: PTON ) -7% on disappointing guidance . FireEye (NASDAQ: FEYE ) -7% on Q4 earnings . Aduro BioTech (NASDAQ: ADRO ) -6% . Golar LNG Partners (NASDAQ: GMLP ) -6% . Kellogg (NYSE: K ) -6% after profit outlook disappoints. NanoViricides (NYSEMKT: NNVC ) -6% . Intelsat S.A. (NYSE: I ) -6% on report of Chapter 11 consideration. Co-Diagnostics (NASDAQ: CODX ) -5 …

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss | Zacks | 2/6/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article ABIOMED, Inc. ( ABMD - Free Report ) reported third-quarter fiscal 2020 earnings per share (EPS) of $1.51, outpacing the Zacks Consensus Estimate of $1.09. The figure surged 55.7% year over year. The Zacks Rank 4 (Sell) company’s revenues came in at $221.6 million, which lagged …

Abiomed (ABMD) Initiated with a Hold at BTIG | 2/6/2020

… ABMD ) received a Hold rating from BTIG analyst Marie Thibault yesterday. The company’s shares closed last Monday at $190.73. The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Abiomed with a $219.00 average price target. See today’s analyst top recommended stocks Based on Abiomed’s latest earnings release for the quarter ending September 30, the company reported a quarterly net profit of $13.07 million. In …

Abiomed: Fiscal 3Q Earnings Snapshot | 2/6/2020

DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Thursday reported fiscal third-quarter net income of $69.2 million. On a per-share basis, the Danvers, Massachusetts-based company said it had profit of $1.51. Earnings, adjusted for non-recurring gains and pretax gains, came to $1.11 per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.09 per …

8-K - ABIOMED INC (0000815094) (Filer) | 2/6/2020

Mailing Address 22 CHERRY HILL DRIVE DANVERS MA 01923 Business Address 22 CHERRY HILL DR DANVERS MA 01923 9787775410 ABIOMED INC (Filer) CIK : 0000815094 042743260 State of Incorp.: DE Fiscal Year End: 0331 Type: 8-K Act: 34 File No.: 001-09585 Film No.: 20580890 SIC : 3841 Surgical & Medical Instruments & ApparatusOffice of Life Sciences …

Abiomed: Fiscal 3Q Earnings Snapshot - The Edwardsville Intelligencer | 2/6/2020

DANVERS, Mass. (AP) _ Abiomed Inc. (ABMD) on Thursday reported fiscal third-quarter net income of $69.2 million. On a per-share basis, the Danvers, Massachusetts-based company said it had profit of $1.51. Earnings, adjusted for non-recurring gains and pretax gains, came to $1.11 per share. The results topped Wall Street expectations. The average estimate of six analysts surveyed by Zacks Investment Research was for earnings of $1.09 per …

Look for Shares of Abiomed Inc to Potentially Rebound after Yesterday’s 1.70% Sell Off | 2/6/2020

Look for Shares of Abiomed Inc to Potentially Rebound after Yesterday’s 1.70% Sell Off 12:50pm By Amy Schwartz Abiomed Inc ( NASDAQ:ABMD ) traded in a range yesterday that spanned from a low of $171.15 to a high of $175.84. Yesterday, the shares fell 1.7%, which took the trading range below the 3-day low of $184.85 on volume of 815,000 shares. Often times after large one-day declines, short-term …

Abiomed Announces Q3 FY 2020 Revenue of $222 Million and 31.7% Operating Margin | BioSpace | 2/6/2020

Abiomed Announces Q3 FY 2020 Revenue of $222 Million and 31.7% Operating Margin Published: Feb 06, 2020 Feb. 6, 2020 12:00 UTC DANVERS, Mass.–( BUSINESS WIRE )– Abiomed . (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported third quarter fiscal 2020 revenue of $221.6 million, an increase of 10% compared to revenue of $200.6 million for the same period of fiscal 2019. Operating income was $70.3 …

Abiomed, Inc. (NASDAQ: ABMD): Q3 2020 Earnings Snapshot | 2/6/2020

Abiomed, Inc. (NASDAQ: ABMD): Q3 2020 Earnings Snapshot February 6, 2020 — Medical device maker Abiomed , Inc. ( NASDAQ: ABMD ) reported net income of $69.2 million or $1.51 per share for the third quarter of 2020, vs. $1.09 per share expected. — Revenue increased 10% annually to $221.6 million during the three-month period, vs. $226.99 million expected — US revenue rose 8% to $185.6 million, while overseas revenue moved up 29% to $36 …

ValuEngine Upgrades ABIOMED (NASDAQ:ABMD) to Buy - Ticker Report | 2/5/2020

ValuEngine upgraded shares of ABIOMED (NASDAQ:ABMD) from a hold rating to a buy report report published on Saturday morning, ValuEngine reports. A number of other research analysts have also recently issued reports on ABMD. Leerink Swann lifted their target price on ABIOMED from $195.00 to $240.00 and gave the company an outperform report on Friday, November 1st. Raymond James cut ABIOMED from an outperform rating to a market perform …

Wall Street Analyst Actions To Watch: The RealReal, Inc.(REAL) , Abiomed, Inc.(ABMD) | 2/5/2020

… recommendation of Abiomed, Inc. from top Wall Street analysts is a Moderate Buy . That is based on 3 analysts who work on the Street. Based on 3 analysts offering 12 month price targets for Abiomed in the last 3 months. The average price target is $219.00 with a high forecast of $240.00 and a low forecast of $198.00. The average price target represents a 14.72% increase from the last price …

Global Cardiovascular Surgical Devices and Technologies Market Research Report 2020 | 2/5/2020

… Surgical Devices and Technologies Product Introduction, Application and Specification 7.1.3 Abbott Cardiovascular Cardiovascular Surgical Devices and Technologies Production Capacity, Revenue, Price and Gross Margin (2015-2020) 7.1.4 Abbott Cardiovascular Main Business and Markets Served 7.2 Abiomed 7.2.1 Abiomed Cardiovascular Surgical Devices and Technologies Production Sites and Area Served 7.2.2 Abiomed Cardiovascular Surgical Devices and Technologies Product Introduction, Application and Specification 7.2.3 Abiomed Cardiovascular Surgical Devices and Technologies Production Capacity, Revenue, Price …

ABIOMED, Inc. (NASDAQ:ABMD) Shares Bought by Beacon Investment Advisory Services Inc. | 2/4/2020

Beacon Investment Advisory Services Inc. raised its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 2,764.9% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,338 shares of the medical equipment provider’s stock after buying an additional 69,813 shares during the period. Beacon Investment Advisory Services Inc. owned about 0.16% of ABIOMED worth $12,340,000 …

ABIOMED, Inc. (NASDAQ:ABMD) Receives Consensus Recommendation of “Hold” from Brokerages | Daily Political | 2/4/2020

Shares of ABIOMED, Inc. (NASDAQ:ABMD) have received an average rating of “Hold” from the eleven ratings firms that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have given a hold recommendation and four have assigned a buy recommendation to the company. The average 1 year price objective among analysts that have issued a report on the stock in …

ABIOMED, Inc. (NASDAQ:ABMD) Shares Sold by Retirement Systems of Alabama | 2/4/2020

Retirement Systems of Alabama trimmed its stake in ABIOMED, Inc. (NASDAQ:ABMD) by 53.3% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 47,851 shares of the medical equipment provider’s stock after selling 54,649 shares during the quarter. Retirement Systems of Alabama owned approximately 0.11% of ABIOMED worth $8,163,000 at the end of the most recent quarter. Several …

Feb 04, 2020 - Allen Investment Management LLC Buys Raytheon Co, Boeing Co, PowerShares QQQ Trust Ser 1, Sells Alerian MLP ETF, IQVIA Holdings Inc, Netflix Inc - GuruFocus.com | 2/4/2020

New York, NY, based Investment company Allen Investment Management LLC ( Current Portfolio ) buys Raytheon Co, Boeing Co, PowerShares QQQ Trust Ser 1, SPDR S&P 500 ETF Trust, CarGurus Inc, sells Alerian MLP ETF, IQVIA Holdings Inc, Netflix Inc, Coupa Software Inc, Abiomed Inc during the 3-months ended 2019Q4, according to the most recent filings of the investment company, Allen Investment Management LLC. As of 2019Q4, Allen Investment Management …

ABIOMED, Inc. (NASDAQ:ABMD) Shares Bought by Beacon Investment Advisory Services Inc. - Ticker Report | 2/4/2020

Beacon Investment Advisory Services Inc. raised its holdings in ABIOMED, Inc. (NASDAQ:ABMD) by 2,764.9% during the fourth the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 72,338 shares of the medical equipment provider’s stock after buying an additional 69,813 shares during the period. Beacon Investment Advisory Services Inc. owned about 0.16% of ABIOMED worth $12,340,000 as of its …

Food and Drug Administration

Cardiac Assist Devices & Equipment: Global Market Report 2020 - ResearchAndMarkets.com | Business Wire | 11/7/2019

… to $1.14 billion at a CAGR of 5.5% through 2022. Major players in the market are Abbot Laboratories, Berlin Heart, Abiomed, Bivacor and Calon Cardio - Technology Ltd. In 2018, North America was the largest region … cost effectiveness due to its miniaturized design. In April 2019, Food and Drug Administration (FDA),a federal agency of US department of health and human services, a regulatory body, has sent a product recall notice …

Global Cardiac Assist Devices & Equipment Market Analysis 2015-2019 & Forecast to 2030: Ventricular Assist Devices (LVAD), Intra-Aotic Baloon Pumps, Total Artificial Heart | Globe Newswire | 11/7/2019

… to $1.14 billion at a CAGR of 5.5% through 2022. Major players in the market are Abbot Laboratories, Berlin Heart, Abiomed, Bivacor and Calon Cardio - Technology Ltd.In 2018, North America was the largest region in … more cost effectiveness due to its miniaturized design.In April 2019, Food and Drug Administration (FDA),a federal agency of US department of health and human services, a regulatory body, has sent a product recall notice …

Clinical Data

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump – Company Announcement - FT.com | Financial Times | 10/31/2019

… at Cleveland Clinic , Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed ’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist . Ed Soltesz , MD … device in the history of the FDA with real world clinical data on more than 100,000 patients and more than 550 peer-reviewed publications. In Europe , the Impella 2.5, Impella CP and Impella CP with …

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump | Business Wire | 10/31/2019

… at Cleveland Clinic , Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist . Ed Soltesz, MD, Mark … device in the history of the FDA with real world clinical data on more than 100,000 patients and more than 550 peer-reviewed publications. In Europe, the Impella 2.5, Impella CP and Impella CP with …

AdvaMed

Impella Featured as an Innovative Technology at U.S. Capitol Event Showcasing Improvements to Women’s Health | Business Wire | 6/14/2019

DANVERS, Mass.- Abiomed’s (NASDAQ:ABMD) Impella platform is being featured today at a Washington, D.C., event showcasing innovations in medical technology that improve healthcare for women. Abiomed’s participation supports its Women’s Initiative for Heart Recovery , which provides education and raises awareness of women’s cardiovascular diseases and the opportunity for heart recovery. The event, hosted by AdvaMed , brings together members of Congress and their staff at the Rayburn House Office Building …

CVS Health

Keep an Eye on Earnings: Cramer’s ‘Mad Money’ Recap (Friday 2/7/20) - TheStreet | 2/8/2020

… still a comeback story, Cramer said, but he was bullish on Lyft. The earnings really kick in on Wednesday with CVS Health ( CVS ) - Get Report , Shopify ( SHOP ) - Get Report and Barrick Gold ( GOLD ) - Get Report … best way to play the return of Boeing BA’s 737Max.” Abiomed ( ABMD ) - Get Report : “I’m sending people to Edwards Lifesciences ( EW ) - Get Report .” Gray Television ( GTN ) - Get Report : “If you want this as a trade …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FRED, CAH, ABMD and CVS | Globe Newswire | 8/27/2019

… earnings. Get additional information about the CAH lawsuit: http://www.kleinstocklaw.com/pslra-1/cardinal-health-inc-loss-submission-form?wire=3 Abiomed, Inc. (NASDAQGS: ABMD) Class Period: January 31, 2019 to July 31, 2019 Lead Plaintiff … www.kleinstocklaw.com/pslra-1/abiomed-inc-loss-submission-form?wire=3 CVS Health Corporation (NYSE: CVS) Class Period: on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for …

CVS

Keep an Eye on Earnings: Cramer’s ‘Mad Money’ Recap (Friday 2/7/20) - TheStreet | 2/8/2020

… still a comeback story, Cramer said, but he was bullish on Lyft. The earnings really kick in on Wednesday with CVS Health ( CVS ) - Get Report , Shopify ( SHOP ) - Get Report and Barrick Gold ( GOLD ) - Get Report … best way to play the return of Boeing BA’s 737Max.” Abiomed ( ABMD ) - Get Report : “I’m sending people to Edwards Lifesciences ( EW ) - Get Report .” Gray Television ( GTN ) - Get Report : “If you want this as a trade …

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FRED, CAH, ABMD and CVS | Globe Newswire | 8/27/2019

… earnings. Get additional information about the CAH lawsuit: http://www.kleinstocklaw.com/pslra-1/cardinal-health-inc-loss-submission-form?wire=3 Abiomed, Inc. (NASDAQGS: ABMD) Class Period: January 31, 2019 to July 31, 2019 Lead Plaintiff … www.kleinstocklaw.com/pslra-1/abiomed-inc-loss-submission-form?wire=3 CVS Health Corporation (NYSE: CVS) Class Period: on behalf of all former Aetna Inc. shareholders who acquired CVS Health Corporation (CVS) shares in exchange for …

Myriad Genetics

The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs | 2/6/2020

… JNCE ) will present at the ASCO-SITC Symposium Phase 1/2 data for vopratelimab, codenamed JTX-2011, in solid tumors. Earnings ABIOMED, Inc. (NASDAQ: ABMD ) (before the market open) Bristol-Myers Squibb Co (NYSE: BMY ) (before … the close) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) (after the close) Myriad Genetics, Inc. (NASDAQ: MYGN ) (after the close) Seattle Genetics, Inc. (NASDAQ: SGEN ) (after the close) Natus Medical Inc (NASDAQ: NTUS ) (after the close) LeMaitre …

The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus | 2/2/2020

… NASDAQ: CSII ) (after the close) Misonix Inc (NASDAQ: MSON ) (after the close) SurModics, Inc. (NASDAQ: SRDX ) (after the close) Thursday ABIOMED, Inc. (NASDAQ: ABMD ) (before the market open) Bristol-Myers Squibb Co (NYSE: BMY ) (before … the close) Enanta Pharmaceuticals Inc (NASDAQ: ENTA ) (after the close) Myriad Genetics, Inc. (NASDAQ: MYGN ) (after the close) Seattle Genetics, Inc. (NASDAQ: SGEN ) (after the close) Natus Medical Inc (NASDAQ: NTUS ) (after the close) LeMaitre …

Medtronic

Global Ventricular Assist Devices Market Analysis, Trends, and Forecasts 2019-2025 - ResearchAndMarkets.com | Business Wire | 11/1/2019

Abiomed , Inc. Berlin Heart GMBH Bivacor, Inc. Calon Cardio-Technology Ltd. Cardiobridge GMBH Evaheart Heartware International Jarvik Heart, Inc. Medtronic Plc Reliantheart Syncardia Systems Llc Tandemlife Terumo Corporation For more information about this report visit https://www.researchandmarkets.com/r/778sbk Contacts ResearchAndMarkets.com Laura Wood, Senior Press Manager [email protected] For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 …

Ventricular Assist Devices Markets, 2025 - Global Market is Projected to Grow by US$1 Billion | PR Newswire | 11/1/2019

Abiomed , Inc. Berlin Heart GMBH Bivacor, Inc. Calon Cardio-Technology Ltd. Cardiobridge GMBH Evaheart Heartware International Jarvik Heart, Inc. Medtronic Plc Reliantheart Syncardia Systems Llc Tandemlife Terumo Corporation For more information about this report visit https://www.researchandmarkets.com/r/8sl67r Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. Media Contact: Research and Markets Laura Wood , Senior Manager [email protected] For E.S.T Office Hours Call +1-917-300-0470 …

Boston Scientific

Impressive Near-Term Outlook for Medical Instruments Industry - October 31, 2019 - Zacks.com | 10/31/2019

… industry are Intuitive Surgical, Inc. ( ISRG - Free Report ) , IDEXX Laboratories, Inc. ( IDXX - Free Report ) , Hologic, Inc. ( HOLX - Free Report ) and Abiomed, Inc. ( ABMD - Free Report ) . Here are the three major industry themes: M&A Trend … dominated the M&A space in 2019 with Thermo Fisher, Boston Scientific (BSX), Medtronic and 3M Co ( MMM - Free Report ) being the prime line acquirers. Boston Scientific’s recently-completed $4.2 billion acquisition of BTG Plc …

Cardinal Health

The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of FRED, CAH, ABMD and CVS | Globe Newswire | 8/27/2019

… would close. Get additional information about the FRED lawsuit: http://www.kleinstocklaw.com/pslra-1/freds-inc-loss-submission-form?wire=3 Cardinal Health, Inc. (NYSE: CAH) Class Period: March 2, 2015 to May 2, 2018 Lead … pslra-1/cardinal-health-inc-loss-submission-form?wire=3 Abiomed, Inc. (NASDAQGS: ABMD) Class Period: January 31, 2019 to July 31, 2019 Lead Plaintiff Deadline: October 7, 2019 The lawsuit alleges that throughout the …

3 Top Healthcare Stocks to Buy in August | Yahoo News | 8/16/2019

Abiomed (NASDAQ: ABMD) , Trulieve Cannabis (OTC: TCNNF) , and Cardinal Health (NYSE: CAH) . Here’s why. A female pharmacist dispensing medicine to an older man. More Image source: Getty Images. A fallen angel Brian Feroldi (Abiomed): I might sound like a broken record , but I truly believe that Abiomed is an amazing bargain right now. Abiomed is a medical device company that is focused on cardiovascular disease. The company sells a range …

Biogen

Amazon’s Future, Long-Term Care, and Unqiue ETFs | Morningstar | 7/13/2019

Biogen in March when that company’s share price plunged 29% in a single day because of the failure of a late-stage Alzheimer’s drug. Other holdings that have hurt the fund include Abiomed and the biotech firm Alkermes. The fund, though, maintains one of the best records in the Morningstar large-growth category since its inception, thanks to those kinds of picks. Its managers tend to be patient with their …

Zacks Equity Research

ABIOMED (ABMD) Earnings Beat Estimates in Q3, Revenues Miss | Zacks | 2/6/2020

You follow Analyst Blog - edit You follow Zacks Equity Research - edit What would you like to follow? Zacks Equity Research Cancel Read More Hide Full Article ABIOMED, Inc. ( ABMD - Free Report ) reported third-quarter fiscal 2020 earnings per share (EPS) of $1.51, outpacing the Zacks Consensus Estimate of $1.09. The figure surged 55.7% year over year. The Zacks Rank 4 (Sell) company’s revenues came in at $221.6 million, which lagged …

Cleveland Clinic

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump – Company Announcement - FT.com | Financial Times | 10/31/2019

DANVERS, Mass. –(BUSINESS WIRE)–Oct. 31, 2019– Three cardiac surgeons at Cleveland Clinic , Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed ’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist . Ed Soltesz , MD, Mark Anderson , MD, and Danny Ramzy , MD, have each successfully implanted multiple pumps during cardiac procedures at their hospitals. This press release features multimedia. View …

Abiomed Announces Q2 FY 2020 Revenue of $205 Million and 29.4% Operating Margin | Business Wire | 10/31/2019

DANVERS, Mass.- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2020 revenue of $205.0 million, an increase of 13% compared to revenue of $181.8 … with SmartAssist. The first 10 patients were treated at the Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center in Los Angeles. The Impella 5.5 with SmartAssist is being introduced in the U.S. through …

Hackensack Meridian Health

First U.S. Patients Treated with Impella 5.5 with SmartAssist, a Minimally Invasive, Forward Flow Heart Pump – Company Announcement - FT.com | Financial Times | 10/31/2019

DANVERS, Mass. –(BUSINESS WIRE)–Oct. 31, 2019– Three cardiac surgeons at Cleveland Clinic , Hackensack Meridian Health and Cedars-Sinai Medical Center are the first in the United States to implant Abiomed ’s (NASDAQ: ABMD) newest heart pump, the Impella 5.5 with SmartAssist . Ed Soltesz , MD, Mark Anderson , MD, and Danny Ramzy , MD, have each successfully implanted multiple pumps during cardiac procedures at their hospitals. This press release features multimedia. View …

Abiomed Announces Q2 FY 2020 Revenue of $205 Million and 29.4% Operating Margin | Business Wire | 10/31/2019

DANVERS, Mass.- Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart recovery and support technologies, today reported second quarter fiscal 2020 revenue of $205.0 million, an increase of 13% compared to revenue of $181.8 … The first 10 patients were treated at the Cleveland Clinic, Hackensack Meridian Health and Cedars-Sinai Medical Center in Los Angeles. The Impella 5.5 with SmartAssist is being introduced in the U.S. through a controlled …

Henry Ford Hospital

Study Demonstrates Early Use of Impella Can Increase Survival in Cardiogenic Shock; Escalation Protocols Initiated | Business Wire | 9/27/2019

… Abiomed’s (NASDAQ: ABMD) Impella heart pump before revascularization via percutaneous coronary intervention (PCI). The study demonstrates the protocol-based approach to increasing survival rates in cardiogenic shock is reproducible in academic and community hospitals across the United States. Results were presented by William O’Neill, MD, medical director of the Center for Structural Heart Disease at Henry Ford Hospital, during the 31 st Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco …

National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery | Business Wire | 5/21/2019

LAS VEGAS- Abiomed (NASDAQ:ABMD) announces that new data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% native heart … medical director of the Center for Structural Heart Disease at Henry Ford Hospital. “Similar to door-to-balloon time, the adoption of these best practices is an evolution in clinical practice that will benefit our …

Henry Ford Hospital, Detroit MI

Study Demonstrates Early Use of Impella Can Increase Survival in Cardiogenic Shock; Escalation Protocols Initiated | Business Wire | 9/27/2019

… Abiomed’s (NASDAQ: ABMD) Impella heart pump before revascularization via percutaneous coronary intervention (PCI). The study demonstrates the protocol-based approach to increasing survival rates in cardiogenic shock is reproducible in academic and community hospitals across the United States. Results were presented by William O’Neill, MD, medical director of the Center for Structural Heart Disease at Henry Ford Hospital, during the 31 st Transcatheter Cardiovascular Therapeutics (TCT) conference in San Francisco …

National Cardiogenic Shock Initiative (NCSI) with Impella Best Practices Demonstrates 72% Survival with 98% Native Heart Recovery | Business Wire | 5/21/2019

LAS VEGAS- Abiomed (NASDAQ:ABMD) announces that new data from the National Cardiogenic Shock Initiative Study (NCSI) on 171 consecutive AMI cardiogenic shock (AMICS) patients from 35 sites demonstrates 72% survival with 98% native heart … medical director of the Center for Structural Heart Disease at Henry Ford Hospital. “Similar to door-to-balloon time, the adoption of these best practices is an evolution in clinical practice that will benefit our …

Michael R. Minogue

Abiomed Announces Preliminary Q3 FY 2020 Revenue of $222 Million, up 10% Over Prior Year | Business & Finance | manchestertimes.com | Business Wire | 1/13/2020

SAN FRANCISCO–(BUSINESS WIRE)–Jan 13, 2020– Abiomed, Inc. (NASDAQ: ABMD), a leading provider of breakthrough heart support technologies today reported preliminary, unaudited, third quarter fiscal 2020 revenue of approximately $221.6 million, an increase of … protocols and clinical outcomes,” said Abiomed Chairman, President and CEO, Michael R. Minogue. “Our product innovation has never been better with the launch of Impella CP ® and Impella 5.5 ™ with SmartAssist ®. We have our best …

Abiomed Announces Preliminary Q3 FY 2020 Revenue of $222 Million, up 10% Over Prior Year | Malvern Daily Record | 1/13/2020

Abiomed, Inc. ( NASDAQ: ABMD ), a leading provider of breakthrough heart support technologies today reported preliminary, unaudited, third quarter fiscal 2020 revenue of approximately $221.6 million, an increase of 10% compared to revenue of $200.6 million … protocols and clinical outcomes,” said Abiomed Chairman, President and CEO, Michael R. Minogue. “Our product innovation has never been better with the launch of Impella CP ® and Impella 5.5 ™ with SmartAssist ® . We have our best …

Brian Schall

MONDAY DEADLINE ALERT: The Schall Law Firm Announces it is Investigating Claims Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Business Wire | 10/7/2019

… Schall Law Firm , a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Abiomed, Inc. (“Abiomed” or “the Company”) (NASDAQ: ABMD ) for violations of §§10(b) and 20 … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

UPCOMING DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Abiomed, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm | Globe Newswire | 9/23/2019

… ANGELES, The Schall Law Firm , a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Abiomed, Inc. (“Abiomed” or “the Company”) (NASDAQ: ABMD ) for violations of §§10(b) and 20 … click here to participate . We also encourage you to contact Brian Schall of the Schall Law Firm, 1880 Century Park East, Suite 404, Los Angeles, CA 90067, at 424-303-1964, to discuss your rights free of …

Lesley Portnoy

Glancy Prongay & Murray Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Abiomed, Inc. | Globe Newswire | 10/3/2019

… Abiomed, Inc. (“Abiomed” or the “Company”) (NASDAQ: ABMD ) investors who purchased securities between January 31, 2019 and July 31, 2019, inclusive (the “Class Period”). If you are a shareholder who suffered a loss, click here to participate. If you wish to learn more about this action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact Lesley Portnoy, Esquire …

Robert S. Willoughby

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD | Globe Newswire | 10/1/2019

… 2019 19:43 ET Source: Pomerantz LLP NEW YORK, Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc. (“ABIOMED” or the “Company”) (NASDAQ: ABMD) and certain of its officers. The class … can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include …

SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in ABIOMED, Inc. of Class Action Lawsuit and Upcoming Deadline – ABMD | Globe Newswire | 9/24/2019

… LLP NEW YORK, Sept. 24, 2019 (GLOBE NEWSWIRE) – Pomerantz LLP announces that a class action lawsuit has been filed against ABIOMED, Inc. (“ABIOMED” or the “Company”) (NASDAQ: ABMD) and certain of its officers. The class … can be obtained at www.pomerantzlaw.com . To discuss this action, contact Robert S. Willoughby at [email protected] or 888.476.6529 (or 888.4-POMLAW), toll-free, Ext. 9980. Those who inquire by e-mail are encouraged to include …

Phillip Kim

ABMD LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Abiomed, Inc. Investors of Important October 7th Deadline in Securities Class Action – ABMD | Globe Newswire | 9/24/2019

… Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”) of the important October 7, 2019 lead plaintiff deadline in the case. The lawsuit seeks to recover damages for Abiomed investors under the federal securities laws. To join the Abiomed class action, go to http://www.rosenlegal.com/cases-register-1645.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or …

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Abiomed, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ABMD | PR Newswire | 8/10/2019

… Abiomed, Inc. (NASDAQ: ABMD ) from January 31, 2019 through July 31 , 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Abiomed investors under the federal securities laws. To join the Abiomed class action, go to http://www.rosenlegal.com/cases-register-1645.html or call Phillip Kim, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action. NO CLASS HAS YET …

Laurence Rosen

ABMD LOSS NOTICE: ROSEN, A LEADING LAW FIRM, Reminds Abiomed, Inc. Investors of Important October 7th Deadline in Securities Class Action – ABMD | Globe Newswire | 9/24/2019

NEW YORK, Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Abiomed, Inc. (NASDAQ: ABMD) from January 31, 2019 through July 31, 2019, inclusive (the “Class Period”) of the … Prior results do not guarantee a similar outcome. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 40 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll …

ROSEN, A TOP RANKED LAW FIRM, Announces Filing of Securities Class Action Lawsuit Against Abiomed, Inc.; Encourages Investors with Losses in Excess of $100K to Contact the Firm - ABMD | PR Newswire | 8/10/2019

… investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Abiomed, Inc. (NASDAQ: ABMD ) from January 31, 2019 through July 31 , 2019, inclusive (the “Class … secured hundreds of millions of dollars for investors. Contact Information: Laurence Rosen, Esq. Phillip Kim, Esq. The Rosen Law Firm, P.A. 275 Madison Avenue, 34 th Floor New York, NY 10016 Tel: (212) 686-1060 Toll …

Jerome Powell

Wall Street Breakfast: S&P 3000 | Seeking Alpha | 7/11/2019

Abiomed (NASDAQ: ABMD ) led the herd by far, surging a whopping 909% , while fifth best was MarketAxess (NASDAQ: MKTX ), which climbed 487% on a rising tide of interest in electronic bond trading on Wall Street. Firing up the ‘half pointers’ Building on yesterday’s momentum that vaulted the S&P 500 over the 3,000 level, U.S. stock index futures are extending gains by a modest 0.2% . Although Jerome Powell’s congressional testimony …

These are the stocks that have led the S&P 500’s five-year run to 3,000 from 2,000 | Yahoo News | 7/11/2019

… nearly five years after the index hit 2,000. These are the stocks that powered the historic rally. Medical implant manufacturer Abiomed led the herd, surging a whopping 909% since the S&P 500 reached 2,000 … Markets got a boost on Wednesday after Federal Reserve Chair Jerome Powell hinted at cutting rates in his testimony to the House Financial Services Committee. Traders are betting the Fed will deliver an insurance rate …